Randomized, open-label, phase II trial of gemcitabine with or without bavituximab in patients with nonresectable stage IV pancreatic adenocarcinoma.

被引：0
|
作者：
Pandya, Shuchi Sumant
Wong, Lucas
Bullock, Andrea J.
Grabelsky, Stephen A.
Shum, Merrill Kingman
Shan, Joseph
Menander, Kerstin B.
Reid, Tony R.
机构：
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
[2] Scott & White Canc Res Inst, Temple, TX USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] Ctr Hem Onc, Boca Raton, FL USA
[5] Oncol Inst Hope & Innovat, Whittier, CA USA
[6] Peregrine Pharmaceut Inc, Tustin, CA USA
[7] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4054
引用
收藏
页数：1
相关论文
共 50 条
  • [1] NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma.
    Kim, G. P.
    Oberg, A.
    Kabat, B.
    Sing, A.
    Hedrick, E.
    Campbell, D.
    Alberts, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
  • [2] Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma.
    Kim, G. P.
    Foster, N. R.
    Salim, M.
    Flynn, P. J.
    Moore, D. F.
    Zon, R.
    Mowat, R. B.
    Wiesenfeld, M.
    McCullough, A. E.
    Alberts, S. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.
    Neoptolemos, John P.
    Palmer, Dan
    Ghaneh, Paula
    Valle, Juan W.
    Cunningham, David
    Wadsley, Jonathan
    Meyer, Tim
    Anthoney, Alan
    Glimelius, Bengt
    Falk, Stephen
    Segersvard, Ralf
    Izbicki, Jakob R.
    Middleton, Gary William
    Ross, Paul J.
    Wasan, Harpreet
    Mcdonald, Alec
    Crosby, Tom David Lewis
    Psarelli, Eftychia Eirini
    Hammel, Pascal
    Buchler, Markus W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
  • [4] Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial
    Melisi, Davide
    Zecchetto, Camilla
    Merz, Valeria
    Malleo, Giuseppe
    Landoni, Luca
    Quinzii, Alberto
    Casalino, Simona
    Fazzini, Federica
    Gaule, Marina
    Pesoni, Camilla
    Casetti, Luca
    Esposito, Alessandro
    Marchegiani, Giovanni
    Piazzola, Cristiana
    D'Onofrio, Mirko
    de Robertis, Riccardo
    Gabbrielli, Armando
    Bernardoni, Laura
    Crino, Stefano F.
    Pietrobono, Silvia
    Luchini, Claudio
    Aliberti, Camillo
    Martignoni, Guido
    Milleri, Stefano
    Butturini, Giovanni
    Scarpa, Aldo
    Salvia, Roberto
    Bassi, Claudio
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 196
  • [5] A multicenter randomized, open-label, proof-of-concept, phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer.
    Dalgleish, Angus George
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [6] (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial
    Reni, Michele
    Dugnani, Erica
    Cereda, Stefano
    Belli, Carmen
    Balzano, Gianpaolo
    Nicoletti, Roberto
    Liberati, Daniela
    Pasquale, Valentina
    Scavini, Marina
    Maggiora, Paola
    Sordi, Valeria
    Lampasona, Vito
    Ceraulo, Domenica
    Di Terlizzi, Gaetano
    Doglioni, Claudio
    Falconi, Massimo
    Piemonti, Lorenzo
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1076 - 1085
  • [7] A phase I open-label dose-escalation study of AL2846 in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
    Liu, Rui
    Deng, Ting
    Bai, Ming
    Zhang, Le
    Ning, Tao
    Wang, Xia
    Ji, Zhi
    Yang, Yuchong
    Ge, Shaohua
    Li, Hongli
    Duan, Jingjing
    Ba, Yi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
    Dalgleish, Angus G.
    Stebbing, Justin
    Adamson, Douglas J. A.
    Arif, Seema Safia
    Bidoli, Paolo
    Chang, David
    Cheeseman, Sue
    Diaz-Beveridge, Robert
    Fernandez-Martos, Carlos
    Glynne-Jones, Rob
    Granetto, Cristina
    Massuti, Bartomeu
    McAdam, Karen
    McDermott, Raymond
    Munoz Martin, Andres J.
    Papamichael, Demetris
    Pazo-Cid, Roberto
    Vieitez, Jose M.
    Zaniboni, Alberto
    Carroll, Kevin J.
    Wagle, Shama
    Gaya, Andrew
    Mudan, Satvinder S.
    [J]. BRITISH JOURNAL OF CANCER, 2016, 115 (07) : 789 - 796
  • [9] Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
    Angus G Dalgleish
    Justin Stebbing
    Douglas JA Adamson
    Seema Safia Arif
    Paolo Bidoli
    David Chang
    Sue Cheeseman
    Robert Diaz-Beveridge
    Carlos Fernandez-Martos
    Rob Glynne-Jones
    Cristina Granetto
    Bartomeu Massuti
    Karen McAdam
    Raymond McDermott
    Andrés J Muñoz Martín
    Demetris Papamichael
    Roberto Pazo-Cid
    Jose M Vieitez
    Alberto Zaniboni
    Kevin J Carroll
    Shama Wagle
    Andrew Gaya
    Satvinder S Mudan
    [J]. British Journal of Cancer, 2016, 115 : 789 - 796
  • [10] AN OPEN-LABEL MULTICENTER PHASE II TRIAL OF AVISCUMINE IN PREVIOUSLY TREATED PATIENTS WITH UNRESECTABLE STAGE IV METASTATIC MELANOMA
    Uwe, Trefzer
    Ralf, Gutzmer
    Tabea, Wilhelm
    Florian, Schenck
    Katharina, Kaehler C.
    Volkmar, Jacobi
    Klaus, Witthohn
    Hans, Lentzen
    Peter, Mohr
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S7 - S7
12345